Elizabeth Jeffords is currently the Chief Commercial & Strategy Officer for Alkahest, a clinical stage biotech company focused on neurodegenerative and age-related diseases. Prior to joining Alkahest, Elizabeth was a consultant with Tara Health Foundation, where she focused on maternal and infant health. Elizabeth worked for Genentech & Roche for nearly 17 years in various commercial and leadership roles. Most recently she served as the Vice President of US Ophthalmology in South San Francisco, General Manager and CEO of Roche Norway in Oslo, and Global Head of Commercial Operations and Business Unit Head of the Established Products in Basel, Switzerland. Elizabeth also ran the US Strategic Pricing and Contracting Management team, and the Market Analysis & Insights teams at Genentech. Much of her early focus at Genentech was on women’s health and oncology, where she worked on Herceptin, Perjeta, and Kadcyla for Breast Cancer. Prior to Genentech, she worked in bench science at Yale and UCSF, as a strategy consultant, and in Business Development & Marketing at a software start-up. She holds a BS in Biology and Management from Yale University and a Masters of Business and Technology as a Fulbright Scholar from the University of New South Wales in Australia.
Throughout her career she has been passionately involved in Women’s Leadership. Elizabeth volunteers with the HBA as a San Francisco Bay Area Advisor, and served on the Executive Committee and Board of HBA Europe. She’s been actively involved with both the Biotech and Digital Health cohorts of Springboard, and Elizabeth serves as an Angel Investor through the Portfolia Femtech Fund. Elizabeth was named the 2009 HBA Genentech Rising Star, and in 2014 was further named one of the inaugural class of HBA’s Luminaries.